Dermira Inc. (NASDAQ:DERM) traded down 3.2% on Wednesday after an insider sold shares in the company. The stock traded as low as $34.43 and last traded at $34.44, with a volume of 133,543 shares traded. The stock had previously closed at $35.57.
Specifically, insider Eugene A. Bauer sold 2,500 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of $29.48, for a total transaction of $73,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Christopher M. Griffith sold 1,303 shares of the stock in a transaction on Friday, July 15th. The shares were sold at an average price of $30.02, for a total value of $39,116.06. Following the sale, the vice president now owns 44,941 shares of the company’s stock, valued at approximately $1,349,128.82. The disclosure for this sale can be found here. Insiders own 17.30% of the company’s stock.
Several equities analysts recently issued reports on DERM shares. Needham & Company LLC reissued a “buy” rating and issued a $46.00 target price on shares of Dermira in a research report on Wednesday. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Leerink Swann reissued a “buy” rating and issued a $47.00 target price (up from $46.00) on shares of Dermira in a research report on Thursday, June 2nd. Finally, Wedbush upped their target price on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Dermira has an average rating of “Buy” and a consensus target price of $41.00.
The stock’s 50-day moving average is $32.43 and its 200-day moving average is $28.54. The stock’s market cap is $1.22 billion.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by $0.03. On average, analysts predict that Dermira Inc. will post ($3.39) earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,500 shares during the period. Glenmede Trust Co. NA acquired a new position in Dermira during the second quarter valued at approximately $170,000. A.R.T. Advisors LLC acquired a new position in Dermira during the second quarter valued at approximately $207,000. DIAM Co. Ltd. acquired a new position in Dermira during the second quarter valued at approximately $231,000. Finally, Regents of The University of California acquired a new position in Dermira during the first quarter valued at approximately $252,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.